Cancer patients in Minnesota's medical cannabis program reported significant symptom improvement across the board | Research

The takeaway

Cancer patients in Minnesota's medical cannabis program showed significant reductions across all eight symptoms tracked, with 27-50% achieving clinically meaningful improvement lasting at least 4 months.

Cancer patients considering medical cannabis, oncologists, and medical cannabis program administrators.

27-50% achieved meaningful improvement

What the researchers found

Significant reductions were found across all 8 symptoms (anxiety, appetite loss, depression, sleep disturbance, fatigue, nausea, pain, and vomiting) within 4 months of starting medical cannabis. The proportion achieving 30% or greater symptom reduction ranged from 27% (fatigue) to 50% (vomiting). Adverse effects were reported by only 10.5% of patients.

Why it matters

Minnesota's program is unique in routinely collecting standardized symptom data, providing real-world evidence on medical cannabis outcomes in cancer patients at a scale that individual clinical trials rarely achieve.

The numbers in context

All 8 symptoms showed significant reduction (all p < .001). 30% or greater symptom reduction: fatigue 27%, vomiting 50%. Adverse effects in 10.5% of patients. Symptom scores measured at each cannabis purchase over 4 months.

How the study worked

Observational study using patient-reported symptom scores collected routinely by Minnesota's medical cannabis program. Patients rated 8 symptoms at their worst in the last 24 hours before each purchase. Baseline scores were compared with averages over the first 4 months.

What this study cannot tell us

No control group or randomization. Symptom improvement could reflect placebo effect, disease progression, or concurrent treatments. Self-reported data before purchases may reflect selection bias (patients who benefit keep purchasing). Drop-out bias not addressed.

How to read the evidence

Rated moderate because this is a large real-world observational dataset from a structured medical program, though it lacks a control group.

When this study was published

Published in 2019. Minnesota's program has continued collecting data and may have published follow-up analyses.

The bigger picture

This is among the largest real-world datasets on medical cannabis for cancer symptoms. The broad symptom improvement and low adverse effect rate support the tolerability argument, though the lack of a control group limits causal conclusions.

Questions still open

How much of the improvement is attributable to cannabis versus other treatments or natural symptom fluctuation? Do specific cannabinoid formulations work better for specific symptoms? What accounts for the difference between 27% (fatigue) and 50% (vomiting) responder rates?

Common questions

Which cancer symptoms improved most with medical cannabis?

Vomiting had the highest responder rate (50% achieving 30%+ reduction), while fatigue had the lowest (27%). All eight symptoms tracked showed statistically significant improvement overall.

Were there many side effects?

Only 10.5% of patients reported adverse effects, suggesting medical cannabis was well tolerated in this cancer population.

Does this prove cannabis helps cancer symptoms?

It shows a strong association but cannot prove causation because there was no control group. Improvements could partly reflect placebo effects, other treatments, or the fact that patients who do not benefit tend to stop purchasing.

Read the original research

Impact of Medical Cannabis on Patient-Reported Symptoms for Patients With Cancer Enrolled in Minnesota's Medical Cannabis Program.

Journal of oncology practice, 15(4), e338-e345

View on PubMed ↗Publisher’s paper ↗

Citation

Anderson, Susan P; Zylla, Dylan M; McGriff, Deepa M; Arneson, Tom J. (2019). Impact of Medical Cannabis on Patient-Reported Symptoms for Patients With Cancer Enrolled in Minnesota's Medical Cannabis Program.. Journal of oncology practice, 15(4), e338-e345. https://doi.org/10.1200/JOP.18.00562